Etamsylate API Manufacturers

Looking for Etamsylate API 2624-44-4?

Description:

Here you will find a list of producers, manufacturers and distributors of Etamsylate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Etamsylate 

Synonyms:

Ethamsylate  

Cas Number:

2624-44-4 

DrugBank number:

DB13483 

Unique Ingredient Identifier:

24YL531VOH

Etamsylate is a type of Hemostatics

Hemostatics, a subcategory of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in promoting hemostasis, the process of blood clotting, to control bleeding. These essential medical substances are widely used in surgical procedures, trauma cases, and various medical conditions where excessive bleeding is a concern.

Hemostatics function by either promoting the aggregation of platelets or enhancing the coagulation cascade, thus facilitating clot formation and preventing blood loss. Several types of hemostatic agents are available, including topical agents, injectable agents, and absorbable sponges.

Topical hemostatic agents are commonly used in minor surgeries and dental procedures. These agents, such as oxidized regenerated cellulose and gelatin-based products, are applied directly to the bleeding site to induce clot formation and achieve hemostasis.

Injectable hemostatics, on the other hand, are administered intravenously or intramuscularly and work systemically to promote blood clotting. Examples of injectable hemostatics include recombinant factor VIIa and fibrinogen concentrates, which are employed in cases of severe bleeding or hemophilia.

Absorbable sponges, often made of gelatin or collagen, are frequently used in surgical procedures to control bleeding. These sponges absorb blood, swell, and create a physical barrier that supports clot formation.

Hemostatics have revolutionized medical practices by reducing blood loss during surgeries, improving patient outcomes, and minimizing the need for blood transfusions. They have become indispensable tools in various medical specialties, including cardiovascular surgery, orthopedics, and trauma care.

In conclusion, hemostatics are vital pharmaceutical APIs that promote hemostasis and prevent excessive bleeding. Their application in medical procedures ensures efficient clot formation and enhances patient safety.

Etamsylate (Hemostatics), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.

• AXXO GmbH from Germany, product country of origin World
• FSP Galena from Poland, product country of origin Poland

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.